## Disclosures

### Personal Commercial (0)

- No disclosures on record

### Additional Personal Commercial Disclosures for Education Activities (0)

- No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

- No disclosures on record

### Clinical Trial Enroller (5)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Bering</td>
<td>A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of XXX in Subjects with Acute Coronary Syndrome</td>
<td>DalCor Pharma UK, Ltd</td>
</tr>
<tr>
<td>Target BPI</td>
<td>A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population: The dal-GenE trial</td>
<td>DalCor Pharma UK, Ltd</td>
</tr>
<tr>
<td>A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population: The dal-GenE trial</td>
<td>DalCor Pharma UK, Ltd</td>
<td></td>
</tr>
<tr>
<td>Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing XXXXX in Patients Undergoing PCI Due to Acute Coronary Syndrome with NSTEMI</td>
<td>Shaanxi Micot Technology Co. Ltd</td>
<td></td>
</tr>
<tr>
<td>The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study</td>
<td>Svelte Medical Systems</td>
<td></td>
</tr>
</tbody>
</table>

### Institutional Financial Decision-Making Role (0)

- No disclosures on record

### Expert Witness Testimony (0)

- No disclosures on record

---

## Agreement

### Certified Education Attestation

Signed on 7/23/2023

URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement

Signed on 7/23/2023

URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo

Signed on 7/23/2023

URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement

Signed on 7/23/2023

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committee members and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.